LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

LLY

1,043.64

-0.48%↓

JNJ

245.72

-0.16%↓

ABBV

228.55

+0.11%↑

NVS

166.91

+1.63%↑

MRK

124.32

+0.98%↑

Начало・Списък с акции・Cogent Biosciences Inc

Cogent Biosciences Inc

Отворен

38.6 5.18

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

36.94

Максимум

38.98

Ключови измерители
By Trading Economics
Приходи	-7.4M -81M
EPS	-0.5
Служители	205
EBITDA	-6.8M -79M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+39.74% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	3.4B 5.6B
Предишно отваряне	33.42
Предишно затваряне	38.6

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

4.88 / 5.87 Подкрепа & съпротива

Cogent Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.02.2026 г., 22:53 ч. UTC

Придобивния, сливания и поглъщания

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23.02.2026 г., 22:36 ч. UTC

Печалби

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23.02.2026 г., 22:32 ч. UTC

Печалби

Woodside Energy Fiscal Year Net Profit Falls 24%

23.02.2026 г., 23:58 ч. UTC

Пазарно говорене

Печалби

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23.02.2026 г., 23:58 ч. UTC

Пазарно говорене

Печалби

Global Energy Roundup: Market Talk

23.02.2026 г., 23:47 ч. UTC

Пазарно говорене

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23.02.2026 г., 23:43 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23.02.2026 г., 23:41 ч. UTC

Придобивния, сливания и поглъщания

Crescent Capital Partners Owns 53% of ClearView Wealth

23.02.2026 г., 23:40 ч. UTC

Придобивния, сливания и поглъщания

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23.02.2026 г., 23:40 ч. UTC

Придобивния, сливания и поглъщания

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23.02.2026 г., 23:40 ч. UTC

Пазарно говорене

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23.02.2026 г., 23:40 ч. UTC

Придобивния, сливания и поглъщания

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23.02.2026 г., 23:39 ч. UTC

Придобивния, сливания и поглъщания

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23.02.2026 г., 23:31 ч. UTC

Печалби

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23.02.2026 г., 23:31 ч. UTC

Печалби

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23.02.2026 г., 23:28 ч. UTC

Печалби

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23.02.2026 г., 23:28 ч. UTC

Печалби

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23.02.2026 г., 23:28 ч. UTC

Печалби

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23.02.2026 г., 23:27 ч. UTC

Печалби

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23.02.2026 г., 23:24 ч. UTC

Пазарно говорене

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23.02.2026 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23.02.2026 г., 22:31 ч. UTC

Печалби

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23.02.2026 г., 22:24 ч. UTC

Печалби

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23.02.2026 г., 22:22 ч. UTC

Печалби

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23.02.2026 г., 22:22 ч. UTC

Печалби

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23.02.2026 г., 22:22 ч. UTC

Печалби

Viva Energy FY Underlying Ebitda A$700.9 Million

23.02.2026 г., 22:22 ч. UTC

Печалби

Viva Energy Final Dividend 3.94 Australian Cents/Security

23.02.2026 г., 22:21 ч. UTC

Печалби

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23.02.2026 г., 22:21 ч. UTC

Печалби

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23.02.2026 г., 22:20 ч. UTC

Печалби

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Сравнение с други в отрасъла

Ценова промяна

Cogent Biosciences Inc Прогноза

Ценова цел

By TipRanks

39.74% нагоре

12-месечна прогноза

Среден 52.18 USD 39.74%

Висок 67 USD

Нисък 35 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Cogent Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Cogent Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

4.88 / 5.87Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.